Results 11 to 20 of about 329,623 (303)

T cell assays for non-clinical immunogenicity risk assessment: best practices recommended by the European Immunogenicity Platform [PDF]

Frontiers in Immunology
In vitro and in silico tools help drug developers reduce unwanted immunogenicity of biologics at the design stage. These include assays that examine different immune system processes leading to anti-drug antibody (ADA) or cytotoxic cellular response ...
Sophie Tourdot, Anette Christine Karle, Marc Rosenbaum, Chloé Ackaert, Pauline Le Vu, Michael Gutknecht, Maryam Ahmadi, Annelies W. Turksma, Timothy P. Hickling   +8 more
doaj   +2 more sources

A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration [PDF]

, 2014
Strategies to optimize responses to seasonal influenza vaccination in older adults include the use of adjuvants, higher antigen doses, and intradermal delivery.
Castellino, Flora, Clement, Frédéric, Del Giudice, Giuseppe, Della Cioppa, Giovanni, Galli, Grazia, Groth, Nicola, Leroux-Roels, Geert, Levin, Yotam, Lindert, Kelly, Nicolay, Uwe   +9 more
core   +1 more source

Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance

Journal of Immunology Research, 2016
Numbers of biotherapeutic products in development have increased over past decade. Despite providing significant benefits to patients with unmet needs, almost all protein-based biotherapeutics could induce unwanted immunogenicity, which result in a loss ...
Sam Song, Lili Yang, William L. Trepicchio, Timothy Wyant   +3 more
doaj   +1 more source

Trastuzumab immunogenicity development in patients’ sera and in laboratory animals

BMC Immunology, 2021
Background Immunogenicity is a major challenge in drug development and patient care. Clinicians and regulators are familiar with immunogenicity concerns of monoclonal antibody (mAb) therapeutics, growth factors and enzyme replacements.
Lobna Abdel Aziz Kilany, Ayman Abdel Samie Gaber, Mohammad Mabrouk Aboulwafa, Hamdallah Hafez Zedan   +3 more
doaj   +1 more source

Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial [PDF]

, 2018
BackgroundModified Vaccinia Ankara (MVA) is a live, viral vaccine under advanced development as a non-replicating smallpox vaccine. A randomised, double-blind, placebo-controlled phase III clinical trial was conducted to demonstrate the humoral ...
Chaplin, Paul, De Carli, Sonja, Kreusel, Christian, Lawrence, Steven J, Meyer, Thomas P, Nopora, Katrin, Overton, Edgar Turner, Rosch, Siegfried, Samy, Nathaly, Schnidt, Darja, Wagner, Eva, Weidenthaler, Heinz, Young, Philip   +12 more
core   +3 more sources

Molecular cloning and expression of novel fibroblast growth factor-2 conjugated with immunodominant domains of pseudomonas exotoxin [PDF]

, 2015
Angiogenesis is very important in cancer growth and metastasis. Basic fibroblast growth factor (bFGF) as one of the most important angiogenesis factors is an attractive target for cancer vaccine.
Farazmandfar, T., Haghighatfard, H., Hakemi, M.G., Jadidi-Niaragh, F., Samaei, N.M., Yamchi, A., Yazdani, Y.   +6 more
core   +1 more source

Properties of MHC class I presented peptides that enhance immunogenicity. [PDF]

PLoS Computational Biology, 2013
T-cells have to recognize peptides presented on MHC molecules to be activated and elicit their effector functions. Several studies demonstrate that some peptides are more immunogenic than others and therefore more likely to be T-cell epitopes. We set out
Jorg J A Calis, Matt Maybeno, Jason A Greenbaum, Daniela Weiskopf, Aruna D De Silva, Alessandro Sette, Can Keşmir, Bjoern Peters   +7 more
doaj   +1 more source

Conjugate Haemophilus influenzae type b vaccines for sickle cell disease. [PDF]

, 2016
BACKGROUND: People affected with sickle cell disease are at high risk of infection from Haemophilus influenzae type b. Before the implementation of Haemophilus influenzae type b conjugate vaccination in high-income countries, this was responsible for a ...
Allali, Slimane, Ballas, Samir K., Chalumeau, Martin, de Montalembert, Mariane, Launay, Odile   +4 more
core   +2 more sources

Influenza Vaccination of young children or Antibody Immune Response and Protection after Inactivated Influenza Vaccine in Children – A Literature Review [PDF]

, 2020
Influenza virus infection is a major cause of morbidity and mortality in at risk populations. Children, especially under the age of two, are at an increased risk of complications associated with influenza virus infection.
wall, danielle
core   +1 more source

Targeted-pig trial on safety and immunogenicity of serum-derived extracellular vesicles enriched fractions obtained from Porcine Respiratory and Reproductive virus infections [PDF]

, 2018
The Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is the etiological agent of one of the most important swine diseases with a significant economic burden worldwide.
Borrás, Francesc E., del Portillo, Hernando A., Fraile Sauce, Lorenzo José, Montaner Tarbes, Sergio Roberto, Montoya, Maria, Novell, Elena, Tarancón, Vicens   +6 more
core   +4 more sources